Concord Biotech Limited (NSE:CONCORDBIO) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Concord Biotech Limited (NSE:CONCORDBIO) just released its yearly report and things are looking bullish. Results were good overall, with revenues beating analyst predictions by 2.6% to hit ₹12b. Statutory earnings per share (EPS) came in at ₹35.52, some 4.8% above whatthe analysts had expected. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

After the latest results, the five analysts covering Concord Biotech are now predicting revenues of ₹14.5b in 2026. If met, this would reflect a sizeable 21% improvement in revenue compared to the last 12 months. In the lead-up to this report, the analysts had been modelling revenues of ₹14.2b and earnings per share (EPS) of ₹43.09 in 2026. The thing that stands out most is that, while there's been a slight bump in revenue estimates, the consensus no longer provides an EPS estimate. This impliesthat revenue is more important following the latest results.

Check out our latest analysis for Concord Biotech

There's been no real change to the consensus price target of ₹1,934, with Concord Biotech seemingly executing in line with expectations. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. Currently, the most bullish analyst values Concord Biotech at ₹2,110 per share, while the most bearish prices it at ₹1,700. Even so, with a relatively close grouping of estimates, it looks like the analysts are quite confident in their valuations, suggesting Concord Biotech is an easy business to forecast or the the analysts are all using similar assumptions.

Of course, another way to look at these forecasts is to place them into context against the industry itself. It's clear from the latest estimates that Concord Biotech's rate of growth is expected to accelerate meaningfully, with the forecast 21% annualised revenue growth to the end of 2026 noticeably faster than its historical growth of 15% p.a. over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 10% per year. Factoring in the forecast acceleration in revenue, it's pretty clear that Concord Biotech is expected to grow much faster than its industry.

The Bottom Line

The highlight for us was that the analysts increased their revenue forecasts for Concord Biotech next year. Happily, they also upgraded their revenue estimates, and are forecasting them to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

We have estimates for Concord Biotech from its five analysts out to 2028, and you can see them free on our platform here.

Another thing to consider is whether management and directors have been buying or selling stock recently. We provide an overview of all open market stock trades for the last twelve months on our platform, here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.